Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PNT 2003

Next Previous
X
Search
Drug Profile

PNT 2003

Alternative Names: LU 177-SSTR- PNT-2003; LU-177 PNT 2003; Lutetium-177 Octreotate; PNT-2003

Latest Information Update: 01 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator POINT Biopharma
  • Class Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Neuroendocrine tumours

Most Recent Events

  • 27 Dec 2023 POINT Biopharma has been acquired by Eli Lilly and Company
  • 27 Mar 2023 Lantheus and Point Biopharma closes its strategic collaboration and exclusive license agreements for PNT 2002 and PNT 2003
  • 07 Dec 2022 PNT 2003 is still in preclinical for Neuroendocrine Tumour in Canada (Point Biopharma pipeline, November 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top